[Lignes directrices pour le dépistage du VIH, l'hépatite virale et d'autres infections chez les usagers de drogues]
A manual for provider-initiated medical examination, testing and counselling.
Infectious diseases are among the most serious health consequences of injecting drug use and can lead to significant healthcare costs. Injecting drug users are vulnerable to a range of infectious and communicable diseases through a variety of risk behaviours, and because of underlying
conditions such as poor hygiene, homelessness and poverty.
There is a recognised need for guidance on providing IDUs with a medical examination and testing for HIV, viral hepatitis and several other infections on a regular basis. In addition, improving testing uptake in this group would benefit epidemiological surveillance and monitoring as carried out at the national and international level.
These guidelines are accompanied by a recommended package of prevention and primary care in relation to injecting drug users and infections. Treatment and other specialist care are not discussed in detail but are dealt with by indicating referral to appropriate services.
- Date de parution: novembre 2010
- Editeur: European Monitoring Centre for Drugs and drug Addiction (EMCDDA)
[Lignes directrices européennes pour l'assurance de la qualité dans le dépistage du cancer colorectal]
The guidelines on colorectal cancer screening form the third and final set of three cancer screening guidelines on breast and cervical cancer published by the Commission to assist Member States in their screening and early detection programmes.
Today’s publication provides the first ever set of uniform guidelines on all the steps necessary for effective population based colorectal cancer screening in the EU. By implementing them, Member States have the potential to organise their health systems more effectively, including the diagnosis and management of cancers detected in screening. There is good evidence that population-based screening using the EU-recommended test reduces mortality from colorectal cancer by around 15% in people of appropriate age (50 to 74 years) invited to attend screening.
The guidelines, coordinated for the Commission by the International Agency for Research on Cancer (IARC), were developed with the input of over 90 experts from 32 countries, and set a benchmark for best practice in colorectal cancer screening. Widespread application of the Guidelines should also make it easier for experts in the field to exchange information and experience across the EU. This is essential for innovation and continuous quality improvement of existing cancer screening programmes.
- Date de parution: décembre 2010
- Editeur: Publications Office of the European Union